Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Express Scripts
Moodys
Merck
AstraZeneca

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR SYMBICORT


✉ Email this page to a colleague

« Back to Dashboard

505(b)(2) Clinical Trials for Symbicort

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Dosage NCT00812682 ↗ Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler Completed AstraZeneca 2006-09-01 This study will evaluate the perception of the physicians and the patients about the approved adjustable dosing of Symbicort® 160/4,5. Symbicort maintenance dose will be adjusted up and down within the approved dose range of 1x2 - 4x2 inhalations per day, to the level of asthma symptoms. Patients and physicians perception of this new dosing schedule will be evaluated by means of questionnaires completion and direct questioning.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Symbicort

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00159263 ↗ Effect of Symbicort on GR Localisation in Asthma Completed AstraZeneca N/A 2004-11-01 To investigate a possible interaction between formoterol and budesonide on GR-translocation and to compare the effect of different doses of Symbicort (80/4.5 and 2x80/4.5 mcg) with the effect of budesonide (200 mcg and 800 mcg) on GR translocation, and to investigate the effect of the study drugs on exhaled NO (bronchial and alveolar fraction.
NCT00159263 ↗ Effect of Symbicort on GR Localisation in Asthma Completed Imperial College London N/A 2004-11-01 To investigate a possible interaction between formoterol and budesonide on GR-translocation and to compare the effect of different doses of Symbicort (80/4.5 and 2x80/4.5 mcg) with the effect of budesonide (200 mcg and 800 mcg) on GR translocation, and to investigate the effect of the study drugs on exhaled NO (bronchial and alveolar fraction.
NCT00206154 ↗ A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients Completed AstraZeneca Phase 3 2005-04-01 The purpose of this study is to compare a combination asthma drug (Symbicort) with its two components, budesonide and formoterol, taken individually or in combination, and with placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)
NCT00206167 ↗ A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD Completed AstraZeneca Phase 3 2005-04-01 The purpose of this study is to compare Symbicort in a pressurized metered-dose inhaler (pMDI) with formoterol and placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
NCT00235911 ↗ Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting Completed AstraZeneca Phase 3 2003-09-01 The primary objective is to compare the effects of Symbicort SiT and treatment according to NHG-guidelines on bronchial hyperresponsiveness in asthmatic patients, as measured by PD20 histamine, and to validate the Bronchial Hyperresponsiveness Questionnaire (BHQ).
NCT00238784 ↗ SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults Completed AstraZeneca Phase 3 2004-05-01 The purpose of this study is to compare Symbicort Single Inhaler treatment with the Best Conventional Practice in patients with persistent asthma
NCT00242411 ↗ MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults Completed AstraZeneca Phase 4 2004-09-01 The purpose of the study is to compare the efficacy of a flexible dose of Symbicort (budesonide/formoterol) with conventional stepwise best standard treatment in patients with persistent asthma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Symbicort

Condition Name

Condition Name for Symbicort
Intervention Trials
Asthma 84
Chronic Obstructive Pulmonary Disease 15
Chronic Obstructive Pulmonary Disease (COPD) 6
COPD 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Symbicort
Intervention Trials
Asthma 81
Pulmonary Disease, Chronic Obstructive 32
Lung Diseases 32
Lung Diseases, Obstructive 31
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Symbicort

Trials by Country

Trials by Country for Symbicort
Location Trials
United States 581
China 92
Japan 91
Canada 69
Germany 54
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Symbicort
Location Trials
California 24
Texas 24
South Carolina 22
Pennsylvania 22
Florida 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Symbicort

Clinical Trial Phase

Clinical Trial Phase for Symbicort
Clinical Trial Phase Trials
Phase 4 37
Phase 3 67
Phase 2/Phase 3 1
[disabled in preview] 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Symbicort
Clinical Trial Phase Trials
Completed 120
Unknown status 8
Terminated 8
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Symbicort

Sponsor Name

Sponsor Name for Symbicort
Sponsor Trials
AstraZeneca 84
Orion Corporation, Orion Pharma 9
GlaxoSmithKline 6
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Symbicort
Sponsor Trials
Industry 135
Other 42
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
AstraZeneca
Baxter
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.